Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
Reimbursement
LifeScience Weekly Digest: Key Industry Updates (13th – 17th January)
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more
Venteur Announces Strategic Partnership with United Benefit Advisors to Provide Personalized Insurance Solutions to Employers Nationwide
Venteur, a healthcare startup focused on personalized health insurance for employees, has entered a strategic partnership with United Benefit Advisors® (UBA), the nation’s largest independent employee benefits advisory network. Through this collaboration, Venteur’s innovative Individual Coverage Health Reimbursement Arrangement (ICHRA) solutions will now be available to UBA member firms, helping them guide employers in offering … Read more